Clostridium Difficile Infections Pipeline Drugs Analysis Report (2023 Updates): FDA Approvals, Clinical Trials, Therapies, MOA, ROA by DelveInsight | Vedanta Biosciences, Inc., Deinove, Biovertis AG

Clostridium Difficile Infections Pipeline Drugs Analysis Report (2023 Updates): FDA Approvals, Clinical Trials, Therapies, MOA, ROA by DelveInsight | Vedanta Biosciences, Inc., Deinove, Biovertis AG

November 20
12:32 2023
Clostridium Difficile Infections Pipeline Drugs Analysis Report (2023 Updates): FDA Approvals, Clinical Trials, Therapies, MOA, ROA by DelveInsight | Vedanta Biosciences, Inc., Deinove, Biovertis AG
(Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, Clostridium Difficile Infections pipeline constitutes 20+ key companies continuously working towards developing 22+ Clostridium Difficile Infections treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

The Clostridium Difficile Infections Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

 

Clostridium Difficile Infections Pipeline Insight, 2023 report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Clostridium Difficile Infections Market.

 

Some of the key takeaways from the Clostridium Difficile Infections Pipeline Report:

  • Companies across the globe are diligently working toward developing novel Clostridium Difficile Infections treatment therapies with a considerable amount of success over the years. 
  • Clostridium Difficile Infections companies working in the treatment market are Adiso Therapeutics, Deinove, Acurx Pharmaceuticals, Inc, Lumen Bioscience, Inc., Summit Therapeutics, Finch Therapeutics Group, Seres Therapeutics, Vedanta Biosciences, MGB Biopharma, Replidyne, and others, are developing therapies for the Clostridium Difficile Infections treatment 
  • Emerging Clostridium Difficile Infections therapies in the different phases of clinical trials are- ADS024, DNV3837, Ibezapolstat, LMN-201, Ridinilazole, CP101, SER 109, VE303, MGB-BP-3, CRS3123, and others are expected to have a significant impact on the Clostridium Difficile Infections market in the coming years.   
  • In October 2022, Summit Therapeutics presented findings from its Ri-CoDIFy Phase III clinical trial during an oral abstract session at IDWeek 2022. However, the announcement did not include any new information regarding their intentions or strategies concerning ridinilazole.
  • In September 2022, Seres Therapeutics disclosed the conclusion of the rolling submission procedure for its Biologics License Application (BLA) to the US Food and Drug Administration (FDA) for SER-109, aimed at preventing recurrent C. difficile infection (rCDI).
  • In March 2022, Pfizer released findings from its crucial Phase III CLOVER trial, assessing the vaccine candidate PF-06425090’s efficacy in preventing Clostridium difficile infection.
  • In  April 2022, Lumen Bioscience reported advancements in the clinical development of LMN-201, an investigative orally administered combination aimed at managing and preventing C. difficile infection (CDI). These milestones encompass the completion of a Phase 1 inaugural human study, confirming the effective delivery of drug contents through enteric capsules into the gastrointestinal tract.
  • In April 2022, Vedanta Biosciences released findings in the journal Cell Host & Microbe, presenting results from a Phase 1a/1b investigation assessing the safety, tolerance, and colonization patterns of VE303 in healthy adults. VE303, a prospective first-in-class defined bacterial consortium, holds promise as a candidate for preventing recurrent Clostridium difficile infection (CDI).
  • In May 2021, “Summit Therapeutics commenced a randomized, double-blind, active-controlled study to examine the safety and tolerance of ridinilazole in comparison to vancomycin. The trial also aims to evaluate the pharmacokinetics of ridinilazole in adolescent participants, specifically those aged 12 to

 

Clostridium Difficile Infections Overview

Clostridium Difficile Infections, commonly referred to as Clostridium difficile or C. difficile, are a kind of bacterium that can cause colitis, an inflammation of the colon, and life-threatening diarrhea. About half a million infections are caused by this disease annually in the United States, making it the most prevalent cause of infections linked to healthcare settings.

 

Get a Free Sample PDF Report to know more about Clostridium Difficile Infections Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/clostridium-difficile-infections-clostridium-difficile-associated-disease-pipeline-insight

 

Emerging Clostridium Difficile Infections Drugs Under Different Phases of Clinical Development Include:

  • ADS024: Adiso Therapeutics
  • DNV3837: Deinove
  • Ibezapolstat: Acurx Pharmaceuticals, Inc
  • LMN-201: Lumen Bioscience, Inc.
  • Ridinilazole: Summit Therapeutics
  • CP101: Finch Therapeutics Group
  • SER 109: Seres Therapeutics
  • VE303: Vedanta Biosciences
  • MGB-BP-3: MGB Biopharma
  • CRS3123: Replidyne
  • ADS 024: Adiso Therapeutics

 

Clostridium Difficile Infections Route of Administration

Clostridium Difficile Infections pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as 

  • Oral
  • Parenteral
  • Intravenous
  • Subcutaneous
  • Topical

 

Clostridium Difficile Infections Molecule Type

Clostridium Difficile Infections Products have been categorized under various Molecule types, such as

  • Recombinant fusion proteins
  • Small molecule
  • Monoclonal antibody
  • Peptide
  • Polymer
  • Gene therapy

 

Clostridium Difficile Infections Pipeline Therapeutics Assessment

  • Clostridium Difficile Infections Assessment by Product Type
  • Clostridium Difficile Infections By Stage and Product Type
  • Clostridium Difficile Infections Assessment by Route of Administration
  • Clostridium Difficile Infections By Stage and Route of Administration
  • Clostridium Difficile Infections Assessment by Molecule Type
  • Clostridium Difficile Infections by Stage and Molecule Type

 

DelveInsight’s Clostridium Difficile Infections Report covers around 22+ products under different phases of clinical development like

  • Late-stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I)
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration

 

Further Clostridium Difficile Infections product details are provided in the report. Download the Clostridium Difficile Infections pipeline report to learn more about the emerging Clostridium Difficile Infections therapies

 

Some of the key companies in the Clostridium Difficile Infections Therapeutics Market include:

Key companies developing therapies for Clostridium Difficile Infections are – Vedanta Biosciences, Inc., Deinove, Biovertis AG, Lumen Bioscience, ImmuniMed, Deinove, ViroPharma Incorporated, Seres Therapeutics, Acurx Pharmaceuticals, Adiso Therapeutics, Summit Therapeutics, Finch Therapeutics Group, Mikrobiomik Healthcare Company S.L., Crestone, MGB Biopharma, and others.

 

Clostridium Difficile Infections Pipeline Analysis:

The Clostridium Difficile Infections pipeline report provides insights into 

  • The report provides detailed insights about companies that are developing therapies for the treatment of Clostridium Difficile Infections with aggregate therapies developed by each company for the same.
  • It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Clostridium Difficile Infections Treatment.
  • Clostridium Difficile Infections key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
  • Clostridium Difficile Infections Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 
  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Clostridium Difficile Infections market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

 

Download Sample PDF Report to know more about Clostridium Difficile Infections drugs and therapies

 

Clostridium Difficile Infections Pipeline Market Drivers

  • Increasing cases of Clostridium Difficile Infections, increasing consumption of antibiotics are some of the important factors that are fueling the Clostridium Difficile Infections Market.

 

Clostridium Difficile Infections Pipeline Market Barriers

  • However, lack of awareness of the infection, high cost of the diagnostic and treatment of severe infection and other factors are creating obstacles in the Clostridium Difficile Infections Market growth.

 

Scope of Clostridium Difficile Infections Pipeline Drug Insight    

  • Coverage: Global
  • Key Clostridium Difficile Infections Companies: Adiso Therapeutics, Deinove, Acurx Pharmaceuticals, Inc, Lumen Bioscience, Inc., Summit Therapeutics, Finch Therapeutics Group, Seres Therapeutics, Vedanta Biosciences, MGB Biopharma, Replidyne, and others
  • Key Clostridium Difficile Infections Therapies: ADS024, DNV3837, Ibezapolstat, LMN-201, Ridinilazole, CP101, SER 109, VE303, MGB-BP-3, CRS3123, and others
  • Clostridium Difficile Infections Therapeutic Assessment: Clostridium Difficile Infections current marketed and Clostridium Difficile Infections emerging therapies
  • Clostridium Difficile Infections Market Dynamics: Clostridium Difficile Infections market drivers and Clostridium Difficile Infections market barriers 

 

Request for Sample PDF Report for Clostridium Difficile Infections Pipeline Assessment and clinical trials

 

Table of Contents

1. Clostridium Difficile Infections Report Introduction

2. Clostridium Difficile Infections Executive Summary

3. Clostridium Difficile Infections Overview

4. Clostridium Difficile Infections- Analytical Perspective In-depth Commercial Assessment

5. Clostridium Difficile Infections Pipeline Therapeutics

6. Clostridium Difficile Infections Late Stage Products (Phase II/III)

7. Clostridium Difficile Infections Mid Stage Products (Phase II)

8. Clostridium Difficile Infections Early Stage Products (Phase I)

9. Clostridium Difficile Infections Preclinical Stage Products

10. Clostridium Difficile Infections Therapeutics Assessment

11. Clostridium Difficile Infections Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Clostridium Difficile Infections Key Companies

14. Clostridium Difficile Infections Key Products

15. Clostridium Difficile Infections Unmet Needs

16 . Clostridium Difficile Infections Market Drivers and Barriers

17. Clostridium Difficile Infections Future Perspectives and Conclusion

18. Clostridium Difficile Infections Analyst Views

19. Appendix

20. About DelveInsight

 

 

About DelveInsight

 

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research
Contact Person: Gaurav Bora
Email: Send Email
Phone: 8774225362
Address:27 Drydock Ave S. Jones Blvd #2432
City: Boston
State: MA
Country: United States
Website: https://www.delveinsight.com/consulting/asset-prioritizaton-services

Categories